Oral administration of probiotic bacteria, Lactobacillus casei and Bifidobacterium breve, does not exacerbate neurological symptoms in experimental autoimmune encephalomyelitis

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 1, 2010, Pages 116-124

  Kobayashi, Toshihide ^a   Kato, Ikuo ^a   Nanno, Masanobu ^a   Shida, Kan ^a   Shibuya, Kazumoto ^b   Matsuoka, Yoshiaki ^a   Onoue, Masaharu ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE   (Japan)

Author keywords

Bifidobacterium breve strain Yakult (BbY); Experimental autoimmune encephalomyelitis (EAE); Lactobacillus casei strain Shirota (LcS); Multiple sclerosis (MS); Probiotics; Rat

Indexed keywords

ANTIGEN; MYELIN BASIC PROTEIN; PROBIOTIC AGENT;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BACTERIAL STRAIN; BIFIDOBACTERIUM BREVE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG SAFETY; EXPERIMENTAL DESIGN; EXPERIMENTAL MODEL; FEMALE; GUINEA PIG; HOMOGENATE; INFANCY; LACTOBACILLUS CASEI; LEWIS RAT; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; RAT; SENSITIZATION; SPINAL CORD;

ADMINISTRATION, ORAL; ANIMALS; BIFIDOBACTERIUM; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GUINEA PIGS; LACTOBACILLUS CASEI; MALE; MYELIN BASIC PROTEINS; PROBIOTICS; RATS; RATS, INBRED LEW; SPINAL CORD;

BACTERIA (MICROORGANISMS); BIFIDOBACTERIUM BREVE; CAVIA; LACTOBACILLUS CASEI; RATTUS;

EID: 77249102620     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923970903200716     Document Type: Article

References (34)

1. Joint FAO/WHO Working Group. report on drafting guidelines for the evaluation of probiotics in food. London, Ontario, Canada, 2002.
2. Vankerckhoven V., Huys G., Vancanneyt M., Vael C., Klare I., Romond M B. et al. Biosafety assessment of probiotics used for human consumption: recommendations from the EU-PROSAFE project. Trends Food Sci. Technol 2008;19:102-114.
3. Kato I., Endo K., Yokokura T. Effects of oral administration of Lactobacillus casei on antitumor responses induced by tumor resection in mice. Int J Immunopharmacol 1994;16:29-36.
4. Takagi A., Matsuzaki T., Sato M., Nomoto K., Morotomi M., Yokokura T. Inhibitory effect of oral administration of Lactobacillus casei on 3-methylcholanthrene-induced carcinogenesis in mice. Med Microbiol Immunol 1999;188:111-116.
5. Yamazaki. K., Tsunoda A., Sibusawa M., Tsunoda Y., Kusano M., Fukuchi K., et al. The effect of an oral administration of Lactobacillus casei strain Shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. Oncol Rep 2000;7:977-982.
6. Aso Y., Akaza H., Kotake, T., Tsukamoto T., Imai K., Naito S., et al. Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. Eur Urol 1995;27:104-109.
7. Ishikawa H., Akedo I., Otani T., Suzuki T., Nakamura T., Takeyama I., et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005;116:762-767.
8. Ogawa M., Shimizu K., Nomoto K., Takahashi M., Watanuki M., Tanaka R., et al. Protective effect of Lactobacillus casei strain Shirota on Shiga toxin-producing Escherichia coli O157:H7 infection in infant rabbits. Infect Immunol 2001;69:1-1108.
9. Hori T., Kiyoshima J., Shida K., Yasui H. Augmentation of cellular immunity and reduction of influenza virus titer in aged mice fed Lactobacillus casei strain Shirota. Clin Diag Lab Immunol 2002;9:105-108.
10. Matsumoto S., Hara T., Hori T., Mitsuyama K., Nagaoka M., Tomiyasu N., et al. Probiotic Lactobacillus-induced improvement in murine chronic inflammatory bowel disease is associated with the down-regulation of pro-inflammatory cytokines in lamina propria mononuclear cells. Clin Exp Immunol 2005;140:417-426.
11. Shida K., Makino K., Morishita A., Takamizawa K., Hachimura S., Ametani A., et al. Lactobacillus casei inhibits antigen-induced IgE secretion through regulation of cytokine production in murine splenocyte cultures. Int Arch Allergy Immunol 1998;115:278-287.
12. Kato I., Tanaka K., Yokokura, T. Lactic acid bacterium potently induces the production of interleukin-12 and interferon-γ mouse splenocytes. Int J Immunopharmacol 1999;21:121-131.
13. de Waard R., Garssen J., Snel J., Bokken GC., Sako T., Veld JH., et al. Enhanced antigen-specific delayed-type hypersensitivity and immunoglobulin G2b responses after oral administration of viable Lactobacillus casei YIT 9029 in Wistar and Brown Norway rats. Clin Diagn Lab Immunol 2001;8:762-767.
14. de Waard R., Garssen J., Bokken GC., Vos JG. Antagonistic activity of Lactobacillus casei strain Shirota against gastrointestinal Listeria monocytogenes infection in rats. Int J Food Microbiol 2002;73:93-100.
15. de Waard R., Claassen E., Bokken GC., Buiting B., Garssen J., Vos J.G. Enhanced immunological memory responses to Listeria monocytogenes in rodents, as measured by delayed-type hypersensitivity (DTH), adoptive transfer of DTH, and protective immunity, following Lactobacillus casei Shirota ingestion. Clin Diagn Lab Immunol 2003;10:59-65.
16. Kato I., Endo-Tanaka K., Yokokura T. Suppressive effects of the oral administration of Lactobacillus casei on type II collageninduced arthritis in DBA/1 mice. Life Sci 1998;63:635-644.
17. Matsuzaki T., Nagata Y., Kado S., Uchida K., Kato I., Hashimoto S., et al. Prevention of onset in an insulin-dependent diabetes mellitus model, NOD mice, by oral feeding of Lactobacillus casei. APMIS 1997;105:643-649.
18. Mike A., Nagaoka N., Tagami Y., Miyashita M., Shimada S., Uchida K., et al. Prevention of B220+ T cell expansion and prolongation of lifespan induced by Lactobacillus casei in MRL/lpr mice. Clin Exp Immunol 1999;117:368-375.
19. Hendriks JJ., Alblas J., van der Pol SM., van Tol EA., Dijkstra CD., de Vries HE. Flavonoids influence monocytic GTPase activity and are protective in experimental allergic encephalitis. J Exp Med 2004;200:1667-1672.
20. Afzali B., Lombardi G., Lechler R.I, Lord GM. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007;148:32-46.
21. Baken KA., Ezendam J., Gremmer ER., de Klerk A., Pennings JL., Matthee B., et al. Evaluation of immunomodulation by Lactobacillus casei Shirota: immune function, autoimmunity and gene expression. Int J Food Microbiol 2006;112:8-18.
22. Ezendam J., van Loveren H. Lactobacillus casei Shirota administered during lactation increases the duration of autoimmunity in rats and enhances lung inflammation in mice. Br J Nutr 2008;99:83-90.
23. Maassen CB., Claassen E. Strain-dependent effects of probiotic lactobacilli on EAE autoimmunity. Vaccine 2008;26:2056-2057.
24. Matsuzaki T., Saito M., Usuku K., Nose H., Izumo S., Arimura K., Osame M. A prospective uncontrolled trial of fermented milk drink containing viable Lactobacillus casei strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. J Neurol Sci 2005;237:75-81.
25. So JS., Kwon HK., Lee CG., Yi HJ., Park JA., Lim SY., et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol 2008;45:2690-2699.
26. So JS., Lee CG., Kwon H K., Yi H J., Chae CS., Park J et al.Lactobacillus casei potentiates induction of oral tolerance in experimental arthritis. Mol Immunol 2008;46:172-180.
27. Baharav E., Mor F., Halpern M., Weinberger A. Lactobacillus GG bacteria ameliorate arthritis in Lewis rats. J Nutr 2004;134:1964-1969.
28. Kano H., Kaneko T., Kaminogawa S.Oral intake of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 prevents collageninduced arthritis in mice. J Food Prot 2002;65:153-160.
29. Maassen CB., van Holten JC., Balk F., Heijne den Bak- Glashouwer MJ., Leer R., et al. Orally administered Lactobacillus strains differentially affect the direction and efficacy of the immune response. Vet Q 1998;20(Suppl 3):S81-S83.
30. Yokote H., Miyake S., Croxford J.L., Oki S., Mizusawa H., Yamamura, T. NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008;173:1714-1723.
31. Dunn SE., Ousman SS., Sobel RA., Zuniga L., Baranzini SE., Youssef S., et al. Peroxisome proliferator-activated receptor (PPAR) alpha expression in T cells mediates gender differences in development of T cell-mediated autoimmunity. J Exp Med 2007;204:321-330.
32. Teuscher C., Bunn JY., Fillmore PD., Butterfield RJ., Zachary JF., Blankenhorn EP. Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic encephalomyelitis: implications for the genetics of multiple sclerosis. Am J Pathol 2004;165:1593-1602.
33. Spach KM., Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol 2005;175:4119-4126
34. Zorzella SF., Seger J., Martins DR., Pelizon AC., Sartori A. Resistance to experimental autoimmune encephalomyelitis development in Lewis rats from a conventional animal facility. Mem Inst Oswaldo Cruz 2007;102:931-936.